Patients with advanced prostate cancer frequently have a poor prognosis as a result of metastasis and present with high serum PSA levels. There is evidence suggesting that the serine protease activity of PSA could be involved in the invasion and metastasis of prostate cancer. In this study, we determined the effects of PSA and its precursor, pro-PSA, on invasion and the type of bone metastasis.
Introduction
Patients with advanced prostate cancer frequently have a poor prognosis as a result of metastasis. In the US, the 5-year survival rate for men diagnosed with advanced prostate cancer between 1995 and 2001 is only 33.5%, compared with 100% when the cancer is localized at diagnosis. 1 There are several lines of evidence suggesting that the serine protease PSA may be involved in cancer cell invasion. One key feature in the process of invasion and metastasis is the degradation of extracellular matrix. Proteases can promote migration, facilitate ;access to blood vessels and extravasation, and allow the development of tumor at distant sites. The expression of proteases correlates with invasiveness. 2 Serine proteinases, such as plasmin, urokinase-type plasminogen activator and members of the kallikrein family, also contribute to the invasive process. 3 PSA is a 28.4-kDa kallikrein family member with chymotrypsin-like activity. Physiologically, degradation of fibronectin and the gel-forming proteins semenogelins I and II by PSA 4, 5 leads to liquefaction of semen and enhanced sperm motility. 6 In the past decades, the serum PSA test has been used for the diagnosis and monitoring of prostate cancer, as serum PSA levels increase in prostate cancer patients due to an increased release from the prostate. However, its usefulness for screening purposes remains controversial, as the PSA test is not specific for prostate cancer. The disruption of the normal prostatic architecture by prostate growth, BPH and inflammation, including prostatitis, can also lead to elevated serum PSA levels.
PSA is expressed as a prepro-protein and exists in several different molecular forms. Pro-PSA is the latent form of the PSA enzyme and has to be activated extracellularly by the action of specific proteases, most probably kallikrein-2, -4 or -5 [8] [9] [10] The serum PSA test measures total PSA, which consists of all immunodetectable PSA, comprised mostly of free uncomplexed PSA and PSA bound to the protein inhibitor a1-antichymotrypsin (ACT). 11 It also detects pro-PSA, internally cleaved PSA, but not PSA bound to a 2 -macroglobulin. Different molecular forms of PSA may have different functions. Clinically, the presence of internally cleaved PSA has been associated with BPH, 12 whereas pro-PSA appears to be a more specific marker for prostate cancer. 13 In prostate cancer, the median percentage of pro-PSA is 45%, whereas in BPH, no pro-PSA is present. 14 It has also been shown by immunohistochemistry that the percentage of pro-PSA-positive glands increases with higher grade. 15 Furthermore, PSA may be involved in the development of osteoblastic bone metastasis frequently observed in advanced prostate cancer. Apart from its physiological substrates, PSA has been demonstrated in vitro to be able to cleave several additional substrates, [16] [17] [18] which may play a role in bone metastasis. The relevance of PSA in prostate cancer and the biological functions of the different forms of PSA in prostate cancer biology are still largely unknown. We transfected prostate adenocarcinoma cells to secrete either PSA or its precursor pro-PSA to investigate the effects of different forms of PSA on invasion and migration, and on bone phenotype.
Materials and methods

Cell lines and cell culture
Mycoplasma-free human prostate adenocarcinoma DU-145, LNCaP and 22Rv1 cells were obtained from and maintained as recommended by ATCC (Manassas, VA, USA). Rat prostate cancer MatLyLu cells were maintained in RPMI-1640 supplemented with 5% fetal bovine serum and 250 nM dexamethasone (Invitrogen, Burlington, ON, Canada).
Plasmid DNA and transfections DU-145 and MatLyLu cells were stably and inducibly transfected with PSA using the 'complete control system' (Stratagene, La Jolla, CA, USA). First, cells were transfected with the pERV3 plasmid and subsequently with the expression vector, pEGSH, containing the cDNA sequence corresponding to full-length PSA (prepro-PSA) or pre-PSA. Plasmid pERV3 allows transcription of pEGSH in the presence of ponasterone A (Invitrogen), but represses basal transcription in its absence. Cells (4 Â 10 6 ) were transfected with Pst I-linearized pERV3 plasmid DNA, using electroporation. Stable colonies were subcloned using 400 mg ml À1 G418 for DU-145 and 175 mg ml À1 G418 for MatLyLu cells. One stable pERV3-expressing DU-145 or MatLyLu clone with the largest inducible expression using transient transfection with pEGSH-Luc (Stratagene), was selected for subsequent stable transfections with either pEGSH-prepro-PSA or pEGSH-prePSA plasmid (Ase I-linearized), using the same method of electroporation. Stable colonies were selected using 100 mg ml À1 hygromycin B and 400 mg ml À1 G418 (DU-145 transfectants), or 125 mg ml À1 hygromycin B and 175 mg ml À1 G418 (MatLyLu transfectants). Empty vector controltransfected DU-145 and MatLyLu cells were also created. Ponasterone A (1-10 mM) was used to induce the expression of PSA. The full-length human PSA sequence (prepro-PSA) was cloned into the multiple cloning site of the pEGSH plasmid (Stratagene) at the BamH I-Xho I restriction site to generate plasmid pEGSH-prepro-PSA. The pEGSH-prePSA plasmid was created by deletion of the 5 0 GCACCCCTCATCCTGTCTCGG 3 0 sequence coding for the pro-peptide.
Invasion and migration
Migration and invasion of the DU-145 and MatLyLu transfectants was measured using Cultrex invasion kits (Trevigen, Gaithersburg, MA, USA) according to the manufacturer's instructions, using 50 mg/well basement membrane extract for invasion and 0.5% fetal bovine serum in the lower well as chemo-attractant. Calcein AM fluorescence was measured using FLX800 microplate reader (BioTek Instruments, Winooski VT, USA; l exc ¼ 485 nm, l em ¼ 520 nm). The number of invaded or migrated cells was determined using a standard curve relating calcein AM-relative fluorescence units to cell number.
PSA protein expression and quantification
Prostate cancer cells (80% confluency) were washed three times with phosphate-buffered saline, after which serum-free media was added. Serum-free conditions were used to avoid the presence of protein-binding partners present in fetal bovine serum, which may mask the presence and activity of PSA. After 5 days, the medium was collected and the cells were counted. The conditioned medium (CM) was concentrated 30-200-fold. Cell number-standardized CM samples were resolved in non-reducing 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and western blot analysis was carried out as described previously. 19 The amount of PSA in CM and mouse serum was quantified using a commercially available ELISA-kit (Diagnostics Biochem, London ON, Canada) against a standard curve (0.2-50 ng PSA ml
À1
).
Intrafemoral injections
Animal study protocols were approved by the Animal Research Ethics Board of McMaster University (Hamilton ON, Canada). Per group, six male inbred nude (Balb/c nu/nu) mice (Charles River, St Constant, QC, Canada) 5 weeks of age were used. Mice were anesthetized by isoflurane inhalation and the cells (2 Â 10 5 cells in 10 ml) were injected into the distal end of the right femur. Phosphate-buffered saline (10 ml) was injected into the left femur. Control animals, not injected with tumor cells, were included. Twelve days after injection, radiographic scans were taken (system MX-20, Faxitron X-ray, Wheeling, IL, USA). The animals were killed, blood collected, and both femora were dissected, fixed in formalin, decalcified using 10% ethylene dimethyl tetraacetic acid and embedded in paraffin.
PSA induces an osteoblastic bone phenotype AP Cumming et al
Histomorphometry, immunohistochemistry and immunocytochemistry
Tumor burden in the right mouse femora was measured as described previously, 20 using longitudinal sections (3 mm) cut through the middle part of the bone, and stained with hematoxylin and eosin to determine the following parameters: number of osteoclasts and osteoblasts per length of trabecular bone surface (N.Oc and N.Ob. (mm À1 ), respectively), eroded bone surface and osteoid surface as a fraction of the trabecular bone surface (ES/BS, and OS/BS (%), respectively). Immunostaining was performed according to Lhotak et al., 21 using heat-induced antigen retrieval (1 mM ethylene dimethyl tetraacetic acid, 10 mM Tris, pH 9.0 for 20 min) and rabbit prediluted anti-PSA antibody (Novus Biologicals, Littleton, CO, USA).
Statistical analysis
Tumor burden and invasion data were tested for differences between means using two-tailed Student's t-test and Minitab 14 software (Minitab, State College, PA, USA). Histomorphometric data were tested for differences between medians using a one-tailed MannWhitney U-test. Differences were considered significant at Po0.05.
Results
Stably transfected prostate cancer cells secrete PSA or pro-PSA Prostate cancer DU-145 and MatLyLu cells were transfected to inducibly secrete either PSA or pro-PSA. These cells do not express PSA as determined by reverse transcriptase-PCR (data not shown) and ELISA (Table 1) . Numerous stable subclones secreting pro-PSA, named DU-proPSA, were generated. Unfortunately, we were not able to subclone stable colonies of MatLyLu cells that secreted pro-PSA. Similarly, PSA-secreting subclones, named MLL-PSA and DU-PSA, and corresponding empty vector (pEGSH) controls of DU-145 and MatLyLu cells were also generated (DU-E and MLL-EV). The amount of PSA or pro-PSA secreted by the different prostate cancer cell transfectants was quantified using ELISA ( Table 1 6 cells per day. Cell lysates contained only negligible amounts of PSA, the majority was rapidly secreted into the CM. The western blot analysis of medium conditioned by different transfected cells is shown in Figure 1 , as compared with the commercially available active PSA standard or LNCaP CM. Under non-reducing conditions, the enzymatically active PSA standard showed two bands, at 29 and 31 kDa. CM obtained from DU-prepro-PSA subclones presented a band at 29 kDa, whereas DU-and MLL-PSA subclones showed a band at 28 kDa. This difference corresponds well with the deletion of the 0.8 kDa prosequence in the PSA subclones. It also suggests that the major form of PSA found in DU-proPSA-CM was pro-PSA, which was not further cleaved into PSA, and that DU-PSA and MLL-PSA transfectants secreted the free form of PSA. Unlike the other transfectants, the MLL-PSA-2 subclone secreted PSA bound to ACT (Figure 1b) and thus, most likely secreted the active form of PSA. Immunocytochemistry confirmed PSA expression in the transfected tumor cells (Figure 1d ).
Invasive potential of PSA-or pro-PSA-secreting prostate cancer cells
Pro-PSA-secreting subclones (DU-proPSA) showed dramatically increased invasion through basement membrane extract (24-129%) when compared with the invasion of empty vector-transfected control cells (Figure 2a) . DU-proPSA-13 cells showed a statistically significant increase of 129%, compared with empty vector control cells. These pro-PSA-secreting clones also demonstrated increased migration (59-263%). On the other hand, the PSA-secreting clones showed significantly reduced invasion and migration when compared with the DU-E empty vector control cells (62-70% and 59-67%, respectively). Similarly, the PSA-secreting MatLyLu subclones reduced the invasion and migration by 4-34% and 14-42%, respectively (Figure 2b ). When compared with the empty vector control (MLL-EV), a statistically significant decrease in invasion for subclone MLL-PSA-3 and migration for subclone MLL-PSA-2 was observed.
In vivo osteoblastic potential
The effect of PSA expression on bone in vivo was determined after intrafemoral injection of MLL-PSA, empty vector control or parental MatLyLu cells into nude mice. Serum PSA levels were measured 12 days after injection. Mice do not have the KLK3 gene, 22 and consequently, we did not detect PSA in the serum of mice injected with the MatLyLu or MLL-EV cells (Figure 3a) . PSA was present in the serum of mice injected with the MLL-PSA cells, at an average concentration of 0.54±0.34 ng ml
À1
. The mice injected with PSA induces an osteoblastic bone phenotype AP Cumming et al PSA induces an osteoblastic bone phenotype AP Cumming et al subclone MLL-PSA-3 had the highest level of serum PSA. By western blot analysis, PSA protein expression in serum of mice injected with different PSA-secreting MatLyLu subclones was observed at 28 and 96 kDa corresponding to PSA and PSA bound to ACT, respectively (Figure 3b) . Microscopic hematoxylin and eosinstained sections of the mouse femora showed extensive infiltration and replacement of bone marrow by tumor. The bone tumor burden in the animals in the different groups was not significantly different (Figure 3c ). Mice injected with MLL-PSA-2 cells, which showed the lowest amount of serum PSA, also had the lowest tumor burden. Immunohistochemistry confirmed PSA expression in the transfected tumor cells, whereas the parental MatLyLu and empty vector control MLL-EV cell-injected femora were negative (Figures 4a and b) . PSA-staining was observed intracellularly, but also around the cells, consistent with PSA being a secreted protein.
Bone histomorphometry was performed on the hematoxylin and eosin-stained femoral sections (Figures 4c-f) as a measure of the bone reaction induced by the tumor cells. Mice, not injected with tumor cells, were used as controls. In the presence of the parental MatLyLu tumor cells, the mouse femora showed a 9.5-fold decrease in the number of osteoblasts (Figure 5a ) and 4.7-fold decreased osteoid surface (Figure 5c ), respectively, when compared with the non-injected control mice. Conversely, femora injected with MatLyLu cells showed a 12.3-fold increase in the number of osteoclasts (Figure 5b ), resulting in a 14-fold increase in eroded surface (Figure 5d ). All three MLL-PSA subclones induced an increase in the osteoblastic parameters osteoid surface and the number of osteoblasts when compared with the MLL-EV cell-injected femora. For MLL-PSA-1 and MLL-PSA-3 cells, the osteoblastic parameters were significantly increased and were returning to levels close to control, uninjected femora. Concurrently, the MLL-PSA subclones decreased the number of osteoclasts as compared with the empty vector-transfected MLL-EV cells. Femora injected with MLL-PSA-2 cells had the lowest number of osteoclasts. The MLL-PSA clones also induced a significant decrease in eroded bone surface. The X-ray appearance of the femora showed osteolytic areas in the femora injected with MLL-EV cells (Figure 4g ) and MLL parental cells, but less osteolysis and areas of osteosclerosis in MLL-PSA-injected femora (Figure 4h ).
Discussion
The serine protease PSA may be involved in cancer cell invasion. 3, 23 To study the effect of different PSA forms, we created subclones of two different prostate cancer cell lines transfected either prepro-PSA or pre-PSA as an artificial system to force secretion of pro-PSA or PSA, respectively. We set out to inducibly express PSA; however, the system appeared leaky, the induction in general marginal, and its inducer ponasterone A was therefore not used further. Numerous stable cell lines secreted PSA, at levels in the same order of magnitude as secreted by 22Rv1 cells (Table 1) . Webber et al. 3 were the first to demonstrate the involvement of PSA in prostate cancer cell invasion using a neutralizing PSA antibody to decrease Matrigel-invasion of LNCaP cells. The increased invasion and migration we observed in the PSA induces an osteoblastic bone phenotype AP Cumming et al pro-PSA-secreting DU-145 may indirectly confirm the observations by Webber et al., 3 as pro-PSA is the major PSA (480%) secreted by LNCaP cells 19, 24, 25 and would most likely have also been neutralized by the PSA antibody used. Pro-PSA secreted from the DU-proPSA cells is likely not processed further, as DU-145 cells do not express KLK2, 8 KLK4 9 or KLK5, 10 known activators of pro-PSA (data not shown). Unfortunately, we were unable to corroborate our own results using the rat prostate cancer MatLyLu cells, as we did not obtain stable MLL subclones transfected with prepro-PSA. The observed increase in invasion and migration was not due to increased cell proliferation, as we observed no significant effect on cell growth in any of the stably transfected prostate cancer cells (data not shown). Similarly, in PC-3 cells, transfection with full-length PSA does also increase migration without any effect on proliferation. 26 Recently, Misra et al. 27 reported a mechanism of action for PSA when bound to a 2 -macroglobulin in prostate cancer cells. The PSA-a 2 -macroglobulin complex binds to cell surface-bound GRP78 to induce anti-apoptotic and pro-proliferative signaling cascades. However, this mechanism of action of PSA bound to a 2 -macroglobulin did not play a role in our serum-free in vitro model, as western blot analysis showed that there was no a 2 -macroglobulin present in our CM (data not shown). Unfortunately, the effects of PSA on invasion and migration did not correlate with the levels of PSA secreted by the different transfected cell lines. This may be due to varying levels of expression and secretion of different other proteinases or proteinase inhibitors that may cooperate and complement, or inhibit PSA's activity in the different subclones. This is exemplified by the MLL-PSA-2 subclone, the only subclone, where we observed PSA bound to ACT in vitro. The divergent effects on invasion and migration we observed in PSA-and pro-PSA-secreting cells also indicate that different forms of PSA may have different functions, not necessarily related to enzymatic activity. Interestingly, the increased invasion observed in the pro-PSA-secreting subclones may account for clinical observations in which pro-PSA can better distinguish cancer from BPH 13 and the percentage of pro-PSApositive glands correlates with grade. 15 PSA may also be involved in the development of osteoblastic metastasis. Transfection of osteosarcoma Saos-2 cells with PSA leads to increased transcript levels of Runx2, a transcription factor involved in osteoblast differentiation and of osteocalcin, a marker for bone formation. 28 PSA has been demonstrated to cleave several substrates important in bone, including insulinlike growth factor (IGF) binding proteins (BPs)-3 and -4, 16 parathyroid hormone-related protein, 17 and the small latent form of tumor growth factor-b2. 18 PSAmediated cleavage of parathyroid hormone-related protein which stimulates osteoclasts and is associated with osteolysis and humoral hypercalcemia of malignancy 29 leads to inactivation. 17 Cleavage of IGFBP-3 30 and PSA induces an osteoblastic bone phenotype AP Cumming et al -4 31 dissociates IGF-I from the IGF-IGFBP complex to stimulate osteoblast development. 32 PSA-mediated proteolysis of the small latent tumor growth factor-b2 results in activation of tumor growth factor-b, 18 another important stimulator of new bone formation. 33, 34 Bone histomorphometric parameters are indicative of bone reactions. Increases in the number of osteoblasts and the amount of osteoid are indicative of osteoblastic reactions, whereas increases in the number of osteoclasts and the amount of resorbed or eroded surface are observed in osteolysis. 35 MatLyLu cells form predominantly osteolytic lesions, 36 consistent with our observed increase in osteoclastic activity and decrease in osteoblastic activity as compared with tumor-free control bone ( Figure 5 ). Intrafemoral MatLyLu cells are therefore ideal to study the effects of PSA on osteoblastic bone parameters. Consistent with our hypothesis, we observed an increase in the number of osteoblasts and osteoid surface in the femora injected with MLL-PSA cells, when compared with control empty vector-transfected MatLyLu cells. Concomitantly, MLL-PSA cells induced a decrease in the number of osteoclasts and eroded surface. Although bone histomorphometry is more sensitive, the X-ray appearance of the femora also showed osteolytic areas in the femora injected with MLL-EV cells (Figure 4g ), and less osteolysis and osteosclerotic areas in MLL-PSA-1-injected femora (Figure 4h ). The latter pattern is reminiscent of human prostate cancer bone metastasis, which often presents not only with predominantly increased bone formation, but also increased bone resorption. 37 The cleavage of the aforementioned substrates important in the osteoblastic bone reaction presumes activity of PSA contributed by the MLL-PSA cells. We also speculate that the decrease in invasion and migration observed in the DU-PSA and MLL-PSA subclones in vitro is due to enzymatic activity of PSA. PSA may cleave yet unknown substrates, such as proteases necessary for invasion, which are rendered inactive upon cleavage. We determined enzymatic activity using a synthetic chromogenic PSA substrate (S-2586), but the activity of PSA in serum-free CM was too low to be measured reliably, even after concentration of the medium. Our observations, however, do support the presence of active PSA in the PSA-secreting subclones. Mice injected with MLL-PSA-1 and -3 cells demonstrated more than two-fold higher serum PSA values compared with mice injected with MLL-PSA-2 cells which correlated with the osteoblastic parameters, number of osteoblasts and osteoid surface (Figure 5a and c) , where the largest effects were also observed in MLL-PSA-1 and -3 mice. In vitro MLL-PSA-1 and -3 and DU-PSA subclones secreted the free form of PSA as determined by western blot analysis. The band corresponding to PSA presented at a slightly lower molecular weight than PSA secreted by prepro-PSA-transfected cells (illustrated by Figure 1a , left panel, difference in M r between DUproPSA-6 and DU-PSA-7). Moreover, the fact that PSA is found bound to ACT in MLL-PSA-2 cells in vitro and in serum from mice injected with MLL-PSA cells (Figures  1b and 3b) suggests that PSA is secreted in an active form, the form of PSA that ACT predominantly binds to and inhibits. 38 PSA has several biological properties important in invasion and metastasis of prostate cancer. Our in vitro data suggest that PSA may inhibit or increase invasive properties of prostate cancer cells dependent on the specific form of PSA secreted. Moreover, our in vivo data indicate that PSA in the bone microenvironment contributed by metastasizing PSA-expressing tumor cells at least contributes to the osteoblastic phenotype of bone metastasis frequently observed in prostate cancer.
